Michael P. Dube
Known title: VP, Chief Accounting OfficerCIK: 0002019493
Associated companies
Transaction History
| NTLA | ▼ Sell | Open Market | 1,864 | $23K | 10/2/2026 | View on chart |
| NTLA | ▼ Sell | Open Market | 2,641 | $44K | 7/1/2026 | View on chart |
| NTLA | ▲ Buy | Grant | 17,250 | $0 | 3/1/2026 | View on chart |
| NTLA | ▼ Sell | Open Market | 2,989 | $28K | 1/5/2026 | View on chart |
| NTLA | ▼ Sell | Open Market | 1,871 | $33K | 10/1/2025 | View on chart |
| NTLA | ▼ Sell | Open Market | 2,503 | $25K | 7/2/2025 | View on chart |
| NTLA | ▲ Buy | Grant | 14,000 | $0 | 3/1/2025 | View on chart |
| NTLA | ▼ Sell | Open Market | 1,372 | $17K | 1/3/2025 | View on chart |
| NTLA | ▼ Sell | Open Market | 2,012 | $38K | 10/2/2024 | View on chart |
| NTLA | ▲ Buy | Grant | 17,801 | $0 | 7/1/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Intellia Therapeutics Appoints New Chief Medical Officer
Intellia Therapeutics announced the appointment of Jing L. Marantz as its new Chief Medical Officer. This leadership change occurred as the stock recently rose 7.6%, moving away from recent support levels. The news highlights a strategic shift in the company's medical leadership during a period of increased market activity.
Intellia Therapeutics Appoints New Chief Medical Officer. Intellia Therapeutics announced the appointment of Jing L. Marantz as its new Chief Medical Officer. This leadership change occurred as the stock recently rose 7.6%, moving away from recent support levels. The news highlights a strategic shift in the company's medical leadership during a period of increased market activity.